论文部分内容阅读
Dihydroartemisinin(DHA)is a semi-synthetic derivative and the main active metabolite of artemisinin.The purpose of this study was to investigate the effect of DHA on the ulcerative col-itis(UC)in both in vivo and in vitro models.Weight,survival rate,colon length,and Disease Activity Index score were used to evaluate the severity of colitis.Reverse transcription quanti-tative polymerase chain reaction and enzyme-linked immunosorbent assay were used to detect the expressions of cytokines interleukin(IL)-1,IL-1 β,IL-4,IL-6,IL-10,IL-12,and tumor necrosis factor-α(TNF-α).The expressions of Janus kinase 2(JAK2)and signal transducer and activa-tor of transcription 3(STAT3),and the phosphorylation of JAK2(p-JAK2)and STAT3(p-STAT3),were measured by western blot analysis.Western blot analysis and immunohistochemistry were used to detect the expressions of tight junction proteins.We found that the weights and colon lengths of mice in dextran sodium sulfate(DSS)+DHA group were significantly lower and longer than those in the DSS group,respectively.Compared with those in the DSS group,the expres-sions of IL-1 β,IL-6,IL-17,and TNF-α in the DSS+DHA and DSS+5-aminosalicylic acid(5-ASA)groups were decreased,while the expressions of IL-4 and IL-10 were significantly upregulated.DHA largely increased the expressions of zonula occludens-1 and occludin.Western blot analy-sis and/or immunohistochemical staining analysis showed that the expressions of JAK2,STAT3,p-JAK2,and p-STAT3 in DSS+DHA and DSS+5-ASA groups were significantly lower than those in DSS group.DHA has a specific therapeutic effect on UC.The anti-inflammatory mechanism of DHA is related to the blockage of the JAK2/STAT3 signaling pathway.These findings provide evi-dence that DHA may be a useful drug and is expected to become a promising new treatment for human UC.